Gilead Stock News

Sector ETF report for IBB

Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd. , Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd. , Green Cross Corp. (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc.

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more fu

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

The U.S health regulator has declined to approve Gilead Sciences’ injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on Tuesday. In a so-called complete response letter, the U.S. Food and Drug Administration (FDA) cited issues related to the compatibility of the drug, lenacapavir, with the proposed […] The post U.S. FDA declines to approve Gilead’s HIV drug on glass vial concerns first appeared on Medicare News .

Monthly update of the Dividend Champions List. 139 companies declared higher dividends in the past month, with an average increase of 10.54% over their previous payouts.

DUBLIN , March 1, 2022 /PRNewswire/ -- The "Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com''s offering. As per report findings, the global antibody drug conjugate market is expected to surpass US$ 25 billion by 2028, thus registering high CAGR rates. Rising geriatric population associated with high cancer prevalence is one of the major factors which will influence the growth of market. In addition, other factors such as unmet need of targeted cancer therapy, increasing awareness about availability of antibody drug conjugates, rising investments by pharmaceutical companies, development of favorable reimbursement policies, and new product launches will also aid in the growth of market during the forecast period. The report provides comprehensive analysis on the currently available antibody drug conjugates in the market with their commercial information. The report also provides insights into ongoing clinical trials and major antibody drug conjugates in the development, which is expected to enter the market during the forecast period.

The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc''s (NASDAQ: GILD ) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to … Full story available on Benzinga.com

Gilead on Tuesday received a rejection letter for its latest potential first-in-class HIV drug, as the company said the FDA cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with its proposed container vial. Regulators previously slapped a clinical hold on 10 trials studying injectable versions

Shares of Gilead Sciences Inc. were down 1.0% in premarket trading on Tuesday after the company said it received a complete response letter from the Food and Drug Administration regarding its application for an experimental HIV drug. Gilead is seeking FDA approval for lenacapavir, a long-acting HIV-1 capsid inhibitor, for people with multi-drug resistant HIV. The FDA raised questions about the use of a specific type of vial and whether it''s compatible with the drug solution. Gilead said it will use a different type of vial. Gilead''s stock is down 3.3% over the past year, while the broader S&P 500 has gained 14.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

The U.S. FDA has issued Gilead Sciences (GILD) a complete response letter for its New Drug Application for its long-acting HIV medication lenacapavir over the container vial for use.

Shares of Gilead Sciences Inc. GILD, -1.18% were down 1.0% in premarket trading on Tuesday after the company said it received a complete response letter from the Food and Drug Administration regarding

The S&P 500, Nasdaq and Dow Jones industrial average have all entered correction territory within the past month, and investors took the brunt of this.

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ: GILD ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with GILD, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 31 uncommon options trades for Gilead Sciences. This isn''t normal. The overall sentiment of these big-money traders is split between 35% bullish and 64%, bearish. Out of all of the special options we uncovered, 18 are puts, for a total amount of $2,827,287, and 13 are calls, for a total amount of … Full story available on Benzinga.com

Monday afternoon''s top analyst upgrades and downgrades included American Electric, BP, Dollar Tree, Gilead, Lockheed Martin and more.